FDA Form 483

FDA Form 483 is the inspectional observations document an FDA investigator issues to a facility at the conclusion of an inspection. The Form 483 lists conditions the investigator observed that may violate the Federal Food, Drug, and Cosmetic Act or related regulations. It is not a final FDA determination of violation, but it carries significant weight and frequently precedes a Warning Letter, a consent decree, or other enforcement action. The recipient typically has 15 business days to respond in writing with corrective actions.

How an FDA Form 483 works

FDA investigators conduct facility inspections under section 704 of the Federal Food, Drug, and Cosmetic Act. At the close of the inspection, the investigator issues a Form 483 listing observed conditions. The recipient may discuss the observations with the investigator at the closeout meeting and provide preliminary written or verbal responses. The formal written response is due within 15 business days and is the recipient's first chance to address each observation with specificity: the corrective action taken, the corrective action planned, the implementation timeline, and the supporting documentation.

FDA reviews the response and considers it alongside the inspection report (the Establishment Inspection Report, or EIR) in deciding whether to issue a Warning Letter, refer the matter for civil or criminal enforcement, or close the inspection with no further action. A strong Form 483 response often determines whether the matter escalates. Inadequate response is one of the leading triggers for Warning Letter issuance.

When an FDA Form 483 applies

Form 483 issues at the close of any FDA inspection that produces observations: drug manufacturers (cGMP inspections under 21 CFR Parts 210 and 211), 503B outsourcing facilities (cGMP plus 503B-specific guidance), medical device manufacturers (Quality System Regulation inspections), food facilities, biologics manufacturers, and other regulated facilities. Pharmacy compounding facilities operating under section 503A are inspected primarily by state boards but may receive Form 483 if FDA jurisdiction attaches (interstate shipping at scale, office-use compounding without 503B registration, or bulk drug substance violations).

The facility's exposure under a Form 483

The most immediate exposure is the Warning Letter, which becomes a public document on FDA's website and triggers downstream consequences in customer relationships, lender covenants, and M&A diligence. Further escalation paths include consent decree, injunction, recall, import alert, and criminal referral under the Park doctrine of responsible corporate officer liability. The defense framework focuses on the 15-day response: a complete, specific, document-supported response that addresses every observation, demonstrates concrete corrective action, and reflects management commitment to compliance. Inadequate or generic responses materially raise the risk of Warning Letter issuance and further enforcement.

Related terms

• FDA Warning Letter The enforcement document that often follows an inadequate Form 483 response.
• 503A and 503B The two compounding pathways under which Form 483 observations frequently issue, especially for 503B.
• USP 797 and 800 The compounding practice standards whose violations often appear in Form 483 observations.
• OIG self-disclosure The parallel pre-enforcement disclosure mechanism for healthcare program issues distinct from FDA matters.

See also

• Practice area
  FDA Warning Letter Response

  The full defense framework spanning Form 483 response through Warning Letter, consent decree, and beyond.

• Practice area
  Compounding Pharmacy Defense

  The compounding defense pillar spanning 503A and 503B regulatory pathways and FDA inspection response.